ABBV - AbbVie Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
77.62
-0.62 (-0.80%)
As of 12:01PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close78.25
Open78.40
Bid77.72 x 1100
Ask77.73 x 800
Day's Range77.35 - 78.44
52 Week Range73.81 - 100.23
Volume1,475,109
Avg. Volume5,133,564
Market Cap114.755B
Beta (3Y Monthly)0.94
PE Ratio (TTM)22.11
EPS (TTM)3.51
Earnings DateJul 25, 2019 - Jul 29, 2019
Forward Dividend & Yield4.28 (5.47%)
Ex-Dividend Date2019-04-12
1y Target Est90.07
Trade prices are not sourced from all markets
  • Is Abbott Laboratories a Buy?
    Motley Fool4 hours ago

    Is Abbott Laboratories a Buy?

    This stock hasn't delivered much excitement, just great returns.

  • How Do Rate Cuts Impact Healthcare Stocks?
    Market Realist4 hours ago

    How Do Rate Cuts Impact Healthcare Stocks?

    Barclays expects the Fed to cut the rate by 50 basis points in July—three months earlier than previously expected. Barclays expects an additional rate cut by 25 basis points in September.

  • Bayer to Invest 5 Billion Euros in Weedkiller Research
    Zacks2 days ago

    Bayer to Invest 5 Billion Euros in Weedkiller Research

    Bayer (BAYRY) announces that it will invest 5 billion euros in developing new weedkillers amid lawsuits claiming its glyphosate-based weedkillers cause cancer.

  • AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
    Zacks2 days ago

    AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

    In the latest trading session, AbbVie (ABBV) closed at $78.60, marking a -0.11% move from the previous day.

  • J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study
    Zacks2 days ago

    J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study

    J&J's (JNJ) Tremfya meets the primary endpoint in a late stage study that evaluated the efficacy and safety of the drug for treating patients with psoriatic arthritis.

  • Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz
    Zacks2 days ago

    Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz

    Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.

  • Top Ranked Income Stocks to Buy for June 17th
    Zacks2 days ago

    Top Ranked Income Stocks to Buy for June 17th

    Top Ranked Income Stocks to Buy for June 17th

  • Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio
    Zacks2 days ago

    Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

  • Why AbbVie Is a Retiree's Dream Stock
    Motley Fool2 days ago

    Why AbbVie Is a Retiree's Dream Stock

    First, there's that terrific dividend. But AbbVie offers even more.

  • 3 Big Pharma Stocks to Buy Right Now
    Zacks5 days ago

    3 Big Pharma Stocks to Buy Right Now

    These big pharma stocks all have a Zacks Rank 2 or better.

  • Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study
    Zacks6 days ago

    Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study

    Pfizer's (PFE) study on JAK inhibitor Xeljanz XR demonstrates the efficacy of the medicine when used as a monotherapy without methotrexate.

  • PR Newswire7 days ago

    New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 Weeks Presented at EULAR

    - Data from SELECT-EARLY and SELECT-COMPARE show a significantly higher proportion of patients treated with upadacitinib monotherapy or in combination with methotrexate (MTX) maintaining clinical remission ...

  • Top Marijuana Stocks That Pay Dividends
    Investopedia7 days ago

    Top Marijuana Stocks That Pay Dividends

    When most people think of marijuana stocks, the last thing they think of is dividends. The legal marijuana industry is still very young, and new companies in growing industries need money to expand. Furthermore, U.S. investors in the marijuana space tend to currently focus on a handful of Canadian companies which have enjoyed the opportunity to list on U.S. exchanges.

  • 5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
    Motley Fool7 days ago

    5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit

    New blockbusters could be on the way for five drugmakers.

  • 10 Smart Dividend Stocks for the Rest of the Year
    InvestorPlace8 days ago

    10 Smart Dividend Stocks for the Rest of the Year

    The market has managed to back itself away from imminent danger, bouncing back from a relatively serious stumble from a couple of weeks ago. It's too soon to say stocks will be able to remain out of trouble, though. Aside from a lethargic time of year, the wrong headline could still easily up-end it all.Or, perhaps the market will continue to climb.In an uncertain environment like the one we find ourselves in now, sometimes the right strategic move is to simplify. Step into reliable cash cows, accumulate cash from dividends, and wait for a more opportune time to make risky bets.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe $64,000 question is, of course, which dividend stocks? They certainly aren't all built the same. * 7 Dark Horse Stocks Winning the Race in 2019 Here's a run-down of 10 different dividend stocks to buy, from a variety of industries. Investors won't necessarily need all of them to create a more defensive-minded portfolio, though considering more than one might not be a bad idea either. Dividend Stocks to Buy: Microsoft (MSFT)Source: Shutterstock Dividend Yield: 1.4%The 1.4% yield on shares of software giant Microsoft (NASDAQ:MSFT) stock isn't exactly jaw-dropping. But this name is a healthy combination of income of well-shielded growth that could resist marketwide weakness should trouble arise.The key is the ongoing shift in the company's business model. Rather than sell software via a one-time purchase (and hope that customer chooses Microsoft again when it comes time for an upgrade), Microsoft is increasingly looking to "rent" access to wares for a nominal monthly fee. The end result is reliable recurring revenue driven by everything from its Azure cloud-management platform to its office-productivity suites to games played on its Xbox franchise.The company is a bit cryptic when it comes to explaining how much of its business is repeat business, but of last quarter's $30.6 billion in revenue, "commercial cloud" products like Azure, Office 365 and LinkedIn -- which are subscription-based -- generated $9.6 billion in sales. AbbVie (ABBV)Source: Shutterstock Dividend Yield: 5.5%Drugmaker AbbVie (NYSE:ABBV) has been a tough name to own of late. Shares are down 33% from their early 2018 peak, mostly in response to patent woes. The primary U.S. patent on its Humira -- which accounts for more than half of its sales -- has expired, which threatens a huge chunk of its business.That generic threat (in the U.S. anyway) won't materialize until 2023, however. That's when the recently approved biosimilar Hyrimoz, from Novartis (NYSE:NVS) subsidiary Sandoz will become available. * 7 Stocks to Buy for the Coming Recession That clearly puts a countdown timer on ABBV stock and its capacity to pay a dividend, and other Humira-related patents are scheduled to expire in the meantime. It's mostly incorrect to say that Humira sales are on the verge of collapse, though. In turn, the company shouldn't have any trouble supporting its current dividend for the foreseeable future.The yield? A very attractive 5.5%. Waste Management (WM)Source: Shutterstock Dividend Yield: 1.8%When most investors look for dividend stocks to buy, they first and foremost consider utilities, banks and real estate investment trusts, and for good reason. These types of companies are well suited to drive reliable, recurring revenue that's relatively easy to pass along to shareholders.There's an oft-overlooked area, however, that's even more recession-proof than utility companies are. In good times and bad, humans are always going to produce garbage … as in literal trash.Enter Waste Management (NYSE:WM) -- a company that hasn't failed to grow its top line in any quarter since the beginning of 2016, and has never been in any serious dire straits. Income has grown about as consistently, even if never at breakneck speeds.It's anything but sexy, and the present yield of 1.9% isn't exactly thrilling. Given its defensive nature on top of reinvesting the regular income it offers though, WM stock has averaged an annual return of nearly 19% over the course of the past ten years. Exxon Mobil (XOM)Source: Shutterstock Dividend Yield: 4.6%The good news is, the trouble crude oil prices and energy stocks were in back in 2014 and 2015 is in the past. The bad news is, crude prices are stabilizing (more or less) at values that allow all energy companies to thrive.It's a scenario that actually plays into the hand that a huge name like Exxon Mobil (NYSE:XOM) is holding. It has the size and scale smaller players don't, allowing it to acquire opportunities as they arise while simultaneously allowing it safely hunker down when oil prices slide lower. * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% Factor in the stock's dividend yield of 4.6%, and what you're left with is a healthy name that's not locked into the broad market's up and downs. Texas Instruments (TXN)Source: Shutterstock Dividend Yield: 2.7%Any name in the semiconductor business can be viewed as a liability in the wrong environment. If there's any worthy exception to that line of thinking, though, it's Texas Instruments (NASDAQ:TXN).Its advantage? It doesn't make the CPUs and GPUs and other high-performance tech that consumer and corporations have to have when times are good, but are shunned when times are bad. Rather, Texas Instruments makes a wide variety of simple and complex technological solutions, many of which you utilize every day without even realizing it, and most of which you've never heard of.That's not to suggest Texas Instruments is bulletproof, because it isn't. Its business still ebbs and flows. Those ebbs and flows aren't sea-sickening though, and the edge is taken off of any big swing by its respectable current yield of 2.7%. Kraft Heinz (KHC)Source: Mike Mozart via FlickrDividend Yield: 5.3%Kraft Heinz (NASDAQ:KHC) shares are down a stunning 66% for the past year, with most of that rout stemming from accounting issues that delayed the company's full-year filing until just last Friday. The stock's jump in response barely made a dent in the stock's long-term demise.Analysts still aren't exactly impressed either. Though closing the internal probe of accounting concerns and bringing in a new CEO to lead a rebuilding effort is a step in the right direction, Credit Suisse's Robert Moskow still has "concerns about business distractions and the investment we think the company will need to make in management talent, brand-building, and product innovation as it tries to pivot to topline growth." Stifel's Christopher Growe isn't a fan either. * 10 Stocks to Buy That Could Be Takeover Targets Investors looking for reliable income won't find many better dividend stocks to buy, however. Thanks to its long-term pullback, KHC now yields a solid 5.3%, and is still earning more than enough to pay its dividend.It's also earning enough to finally stop lowering its dividend, which is something of a victory in and of itself. Verizon Communications (VZ)Source: Shutterstock Dividend Yield: 4.2%No good list of dividend stocks to buy can afford to not name at least one telecom play. Verizon Communications (NYSE:VZ) gets the nod this time around, sporting a yield of 4.2%.Wall Street isn't a huge fan, for the record. Its consensus rating is somewhere between a "buy" and a "hold" thanks to a slew of downgrades since the latter part of last year, and the average price target of $59.64 is only about three points better than the stock's present price. The overarching theme from the pros is simply not enough bank for the bucks Verizon is being forced to spend not to get ahead, but just hold its place relative to its competitors.Verizon does have an advantage though. While in retrospect its acquisition of Yahoo (and the melding of it with AOL) was ill-advised, rival AT&T (NYSE:T) finds itself now bogged down by its video entertainment ambitions, while Sprint (NYSE:S) and T-Mobile US (NASDAQ:TMUS) have essentially conceded defeat as standalone entities.In short, Verizon remains the best-of-breed in a business that isn't ever going to go away. Altria Group (MO)Source: Peyri Herrera via Flickr (Modified)Dividend Yield: 6.1%The smoking cessation movement has been gaining traction in the United States for years. Yet, it would be wrong to say Americans are giving up vices. The decline of the cigarette market has of course been offset by vaping and even a growing interest in hookas -- yes, hookas -- as alternative forms of self-indulgence. Meanwhile, the nation is increasingly embracing and legalizing cannabis.Altria Group (NYSE:MO) hasn't overlooked this consumer shift. It now owns a significant piece of marijuana play Cronos Group (NASDAQ:CRON), and though it has actually backed out of the vaping business for the time being, in April the company got the FDA's green light to sell so-called IQOS devices. It's a hybrid of e-cigs and traditional cigarettes. * The 10 Best Stocks for 2019 -- So Far Altria's dividend is going to remain protected for the foreseeable future, and with its current yield of 6.1% the stock gives income investors a lot to like. U.S. Bancorp (USB)Source: Shutterstock Dividend Yield: 2.8%Large banks have struggled of late, along with their stocks.Most of that weakness has been merited. Aside from the occasional (albeit temporary) inversions of the yield curve that threaten the profitability of lending activities, most of the mega-banks appear to have trouble managing their sheer size when business isn't exactly booming.Not so with smaller, regional banks like U.S. Bancorp (NYSE:USB). By avoiding the more volatile pieces of the banking market like mezzanine loans to shaky corporations or an investment-banking business that has to underwrite wobbly startups, U.S. Bancorp actually finds itself better positioned for lethargic future than many of its peers. Reliability counts.At the bank stock's current price, its dividend yield is a solid 2.8%. Ford Motor (F)Source: FordDividend Yield: 6.1%Finally, add carmaker Ford Motor (NYSE:F) to your list of dividend stocks to buy if you're looking for reliable income in the near future. Its current yield is an incredible 6.1%.In retrospect, the doubters were technically right. Though predicted years too early, the company did hit the headwind shareholders expected it to. This year's top line is projected to slide a little lower, while next year's should be flat.Nevertheless, Ford never imploded the way the stock's multiyear, 50% drubbing suggested was in the cards. The company's still making a ton of money, and still passing a bunch of it along to investors. Namely, it's earned $1.30 per share last year, but only paid 59 cents worth of dividends. There's more than a little wiggle room. * 7 Dark Horse Stocks Winning the Race in 2019 Better yet, now that Ford is (finally) regrouping and rethinking the future of mobility, a rekindled wave of demand for its next-generation vehicles could already be brewing.As of this writing, James Brumley held a long position in Ford and AT&T. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Dark Horse Stocks Winning the Race in 2019 * 6 Chinese Stocks to Sell That Are Suffering From a Digital Ad Slowdown * 4 Technology Stocks Blasting Higher Compare Brokers The post 10 Smart Dividend Stocks for the Rest of the Year appeared first on InvestorPlace.

  • Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II
    Zacks8 days ago

    Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II

    Roche's (RHHBY) hematology portfolio gets a boost as FDA approves Polivy for DLBCL, and lymphoma drug, Gazyva, meets goals in a phase II study.

  • Lilly Announces Tradjenta Cardiovascular Outcome Study Data
    Zacks8 days ago

    Lilly Announces Tradjenta Cardiovascular Outcome Study Data

    Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.

  • PR Newswire8 days ago

    New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance

    - Longer-term results from IMMhance showed 73 percent and 72 percent of patients treated with continuous SKYRIZI™ (risankizumab) experienced complete skin clearance (defined as sPGA 0 and PASI 100, respectively) ...

  • MoneyShow8 days ago

    AbbVie- Unique Mix of Growth, Income Value

    AbbVie (ABBV) is a biotechnology company that is focused on the development and commercializing of treatments in immunology, virology, and oncology, explains growth and income expert Ben Reynolds, editor of Sure Retirement.

  • Horseman Capital Management’s Return, AUM, and Holdings
    Insider Monkey8 days ago

    Horseman Capital Management’s Return, AUM, and Holdings

    Horseman Capital Management is a hedge fund launched in 2000 by John Horseman, with its headquarters located in London (Belgravia) and Jersey, UK. Its founder, John Horseman, has been the fund’s CEO and Director since its launching. He was also the fund’s portfolio manager until 2006 when the position was taken over by Russell Clark, […]

  • Top Ranked Growth Stocks to Buy for June 10th
    Zacks9 days ago

    Top Ranked Growth Stocks to Buy for June 10th

    Top Ranked Growth Stocks to Buy for June 10th

  • Markit9 days ago

    See what the IHS Markit Score report has to say about AbbVie Inc.

    AbbVie Inc NYSE:ABBVView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ABBV with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABBV. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ABBV totaled $6.64 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • CNW Group9 days ago

    AbbVie's MAVIRET™ now listed on the Nova Scotia and Manitoba formularies

    AbbVie's MAVIRET™ now listed on the Nova Scotia and Manitoba formularies

  • AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study
    Zacks12 days ago

    AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study

    AstraZeneca's (AZN) lymphoma drug, Calquence, meets the primary endpoint and a key secondary one in a phase III study for the first-line treatment of chronic lymphocytic leukaemia.